The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

Regular preventive screenings can make a life-changing difference—especially when it comes to cancer. According to the American Cancer Society, colorectal cancer is the third-leading cause of ...

Multitarget stool DNA tests — which are becoming more popular in the United States — have shown increased sensitivity over fecal immunochemical tests (FITs) for early colorectal cancer (CRC) screening ...

An at-home FIT test (Fecal Immunochemical Test) is one of the easiest ways to screen for colon cancer. This short explainer video shows who needs a FIT test, how it works, and how to ask your doctor ...

In the United States, colorectal cancer is the fourth most common kind of cancer and the second-leading cause of cancer deaths, making screening very important.

Pharmacy-based CRC screening programs using FIT can improve early detection, especially in underserved communities, with effective follow-up care. Patients prefer digital updates for negative results ...

Cologuard is a colon cancer screening test you can do at home. It’s a noninvasive, stool-based test that comes in a kit. You use the kit to collect a stool sample. Then you send the sample to a lab ...

A mailed fecal immunochemical test (FIT) outreach followed by patient navigation for those with a positive test increased colorectal cancer (CRC) screening participation at 6 months compared with ...

Colorectal cancer incidence and mortality have increased among younger adults in recent years, with the most significant increase seen in those ages 40 to 49. Starting FIT screening early was tied to ...

Colon cancer is the second-deadliest cancer in the US, partly due to low screening rates. New and emerging screening tools, like blood and breath tests, may offer alternatives to in-office screenings.

Colon cancer is the second-deadliest cancer in America. It's not deadly because it's particularly hard to treat or because oncologists are bad at spotting it. In large part, it's because people aren't ...